Hostname: page-component-cb9f654ff-mnl9s Total loading time: 0 Render date: 2025-08-31T02:21:47.889Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Adult ADHD and Comorbid Depression

Published online by Cambridge University Press:  07 November 2014

Thomas J. Spencer
Get access Rights & Permissions [Opens in a new window]

Extract

As a general principle, separate treatments are often needed for attention-deficit/hyperactivity disorder (ADHD) and comorbid psychiatric disorders. There are few treatments for mood disorders that also treat ADHD, and vice versa. This discussion will review the literature on agents that are effective for both disorders, or that may potentially be combined. Physicians must bear in mind that none of these agents is approved by the Food and Drug Administration for the treatment of comorbid ADHD and depression.

Information

Type
Expert Roundtable Supplement
Information
CNS Spectrums , Volume 13 , Issue S8: Adult Attention-Deficit/Hyperactivity Disorder and the Role of Depression , May 2008 , pp. 14 - 16
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.DuPaul, G, Barkley, R, McMurray, M.Response of children with ADHD to methylphenidate: Interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry. 1994;33:894–903.CrossRefGoogle ScholarPubMed
2.Pliszka, SR.Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry. 1989;28:882–887.CrossRefGoogle ScholarPubMed
3.Taylor, E, Schachar, R, Thorley, G, Wieselberg, HM, Everitt, B, Rutter, M.Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med. 1987;17:121–143.CrossRefGoogle ScholarPubMed
4.Voelker, SL, Lachar, D, Gdowski, LL.The personality inventory for children and response to methylpheni-date: Preliminary evidence for predictive validity. J Pediatr Psychol. 1983;8:161–169.CrossRefGoogle Scholar
5.Livingston, R, Dykman, R, Ackerman, P.Psychiatric comorbidity and response to two doses of methylphe-nidate in children with attention deficit disorder. J Child Adolesc Psychopharmacol. 1992;2:115–122.CrossRefGoogle ScholarPubMed
6.Wilens, T, Prince, J, Spencer, T, et al. Bupropion SR for attention-deficit hyperactivity disorder in adults with bipolar disorder and AD/HD. NCDEU Poster Abstract No. 54;2000. Biol Psychiatry. 2003;54(1):9–16.CrossRefGoogle Scholar
7.Wender, P, Reimherr, F.Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 1990;147:1018–1020.Google ScholarPubMed
8.Biederman, J, Spencer, TJ.Psychopharmacology of adults with attention-deficit/hyperactivity disorder. Primary Psychiatry. 2004;11(7):57–62.Google Scholar
9.Goodman, D. In: Biederman, J, ed. ADHD Across the Life Span: From Research to Clinical Practice—An Evidence-Based Understanding. Hasbrouck Heights, NJ: Veritas, Inc. In press.Google Scholar
10.Wilens, TE, Biederman, J, Prince, J, et al. Six-week, double-blind, placebo-controlled study of desipra-mine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147–1153.Google ScholarPubMed
11.Wilens, TE, Haight, BR, Horrigan, JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793–801.CrossRefGoogle ScholarPubMed
12.Daviss, WB, Bentivoglio, P, Racusin, R, Brown, KM, Bostic, JQ, Wiley, L.Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40(3):307–314.CrossRefGoogle ScholarPubMed
13.Bangs, ME, Emslie, GJ, Spencer, TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407–420.Google ScholarPubMed
14.Spencer, TJ, Biederman, J, Wilens, TE, Faraone, SV.Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry. 2002;63(suppl 12):16–22.Google ScholarPubMed
15.Olvera, RL, Pliszka, SR, Luh, J, Tatum, R.An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol. 1996;6:241–250.CrossRefGoogle ScholarPubMed
16.Birmaher, B, McCafferty, JP, Bellew, KM et al. Comorbid ADHD and disruptive behavior disorders as predictors of response in adolescents treated for major depression. Poster presented at: Annual Meeting of the American Psychiatric Association; May 13–18, 2000; Chicago, IL. Abstract NR562:209.Google Scholar
17.Weiss, M, Hechtman, L.The Adult ADHD Research Group. A randomized double-blind trial of par-oxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 2006;67(4):611–619.CrossRefGoogle ScholarPubMed
18.Gammon, G, Brown, T.Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol. 1993;3:1–10.CrossRefGoogle ScholarPubMed
19.Findling, RL.Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. 1996;6(3):165–175.CrossRefGoogle ScholarPubMed